Catalyst Wire Dossier Catalyst Wire Dossier

Fludarabine, Bendamustine, and Rituximab (FBR)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Fludarabine, Bendamustine, and Rituximab (FBR), covering 2019-09-25 to 2019-09-25. Get the full timeline:

Most recent: Clinical Trial Update: Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

See pricing